Ondine Biomedical Launches Phase 3 Clinical Trial
Ondine Biomedical Inc. (LON: OBI), a leading biopharmaceutical company, is excited to announce the initiation of its extensive Phase 3 clinical trial known as LANTERN. The trial commenced recently with the first patient enrolled. This pivotal study aims to evaluate the effectiveness of the company's cutting-edge non-antibiotic nasal photodisinfection technology, which is designed to prevent surgical site infections.
Details of the LANTERN Study
The LANTERN trial will engage approximately 5,000 patients across 14 hospitals, focusing specifically on the application of Ondine's Steriwave® technology to significantly reduce the risk of infections after surgery. In partnership with HCA Healthcare (NYSE: HCA), the trial will critically compare standard practices of infection prevention with those that integrate Ondine's innovative nasal treatment.
Mechanism of Action
The photodisinfection method utilized in this trial is a swift, five-minute process that efficiently eliminates pathogens from the nasal cavity. It is noteworthy that this technique does not contribute to the growing concern of antimicrobial resistance (AMR). By applying a photosensitive agent inside the nostrils followed by targeted exposure to a specific red light wavelength, the technology generates an oxidative reaction that effectively destroys harmful bacteria, viruses, and fungi.
Importance of the Trial
Carolyn Cross, CEO of Ondine Biomedical, highlighted the trial's importance, noting that the technology offers healthcare professionals an effective tool to swiftly combat infection-causing pathogens without the risks associated with conventional antibiotics, including dependence on patient adherence. This advancement could fundamentally change how infections are managed, particularly in surgical settings.
Targeted Patient Population
The LANTERN study focuses on patients who are undergoing a range of significant surgical procedures, including those related to cardiac, orthopedic, and neurosurgery disciplines. The trial is set to continue enrolling participants until mid-2025, with the first set of preliminary results expected by the autumn of that same year.
Nasal Decolonization Practices
Nasal decolonization stands as a critical component in global healthcare recommendations, aimed at minimizing the risk of surgical site infections. Both the 2016 World Health Organization (WHO) guidelines and updated recommendations from the Society for Healthcare Epidemiology of America in 2023 echo the importance of such practices in enhancing patient safety during and after surgical procedures.
Conclusion and Future Expectations
As the LANTERN trial progresses, Ondine Biomedical remains committed to improving surgical outcomes and tackling the pressing issue of infection following procedures. The initial findings from this study could pave the way for broader adoption of photodisinfection technologies, reinforcing the company's role as a pioneer in the field.
Frequently Asked Questions
What is the LANTERN clinical trial?
The LANTERN clinical trial is a Phase 3 study initiated by Ondine Biomedical to evaluate the effectiveness of their nasal photodisinfection technology in preventing surgical site infections.
How many patients will be involved in the trial?
Approximately 5,000 patients will participate in the LANTERN trial across 14 different hospitals.
What are the benefits of the photodisinfection technology?
This technology is designed to rapidly eliminate pathogens from the nasal cavity without contributing to antimicrobial resistance, offering a crucial advantage over traditional antibiotics.
When are the preliminary results expected?
Preliminary results from the trial are anticipated to be available by the autumn of 2025.
What types of surgeries are being studied in the trial?
The trial focuses on patients undergoing various major surgeries, including cardiac, orthopedic, and neurosurgical procedures.
